CritiTech
CritiTech is a CDMO specializing in drug development and manufacturing, offering proprietary Purcision™ SCP technology and Spray Drying services, with extensive pharmaceutical experience and advanced facilities in Lawrence, Kansas.
Overview of CritiTech
CritiTech is a contract development and manufacturing organization (CDMO) offering comprehensive services throughout the drug development lifecycle. Located at 1849 East 1450 Road, Lawrence, Kansas, CritiTech provides solutions from early-stage development and pre-formulation to GMP production. With more than 125 years of combined pharmaceutical experience, CritiTech is a trusted partner for 'Top 15' pharmaceutical companies.
Proprietary Technologies: Purcision™ SCP and Spray Drying
CritiTech utilizes its proprietary Purcision™ supercritical precipitation (SCP) technology and well-established Spray Drying platforms to support clients in drug development. The Purcision™ technology facilitates the formulation of optimum particle sizes, enhancing drug efficacy, bioavailability, and pharmacokinetics. It is particularly suited for oxygen and water-sensitive compounds, potent and cytotoxic APIs, as well as drugs requiring lifecycle management and bioavailability enhancement.
CritiTech Facilities Expansion
In 2021, CritiTech expanded its facilities to include separate cytotoxic and non-cytotoxic buildings, additional GMP suites, and Fill-Finish capabilities. The facilities feature numerous cGMP manufacturing suites, research and development laboratories, and analytical testing laboratories, enabling CritiTech to handle a wide range of drug development and manufacturing needs.
Drug Development Services
CritiTech offers a variety of drug development services, leveraging platforms like Purcision™ SCP and Spray Drying. These services include method development, validation, material characterization, and analytical testing. The company's Fill-Finish services encompass automated blending, manual and automated capsule filling, and vial filling, ensuring comprehensive support throughout the drug development process.
Current Projects and Advancements
CritiTech has developed four drugs using its Purcision™ SCP technology, with three currently being tested in seven Phase II trials. The technology has been successfully applied to inhaled drug formulations, achieving higher drug concentration and longer duration of action in the lungs, and virtually eliminates residual solvents. CritiTech's scalable and reproducible processes accommodate production scales from milligrams to hundreds of kilograms.